Regenstrief Vice President for Research Development Eneida Mendonca, M.D., PhD, is playing a crucial role in the creation of a groundbreaking publication on artificial intelligence in healthcare from the National Academy of Medicine. The document is viewed as a reference for all stakeholders involved in AI and healthcare. Dr. Mendonca is a co-lead on the chapter considering the tradeoffs and unintended consequences of AI and a co-author on the chapter exploring the deployment of AI in clinical settings. She stresses the importance of carefully monitoring the uses and outcomes after AI implementation to correct any negative consequences and the adoption of general IT governance structures to manage AI. The publication is called “Artificial Intelligence in Health Care: The Hope, The Hype, The Promise, and The Peril.”
-
Research
- Experts
In The News
View All
MedicalXpress quoted Dr. Eric Vachon
Eric Vachon, PhD, R.N., was quoted in MedicalXpress about his...
Influence
View All
Mobile Critical Care Recovery Program for Survivors of Acute Respiratory Failure: A Randomized Clinical Trial
Published in JAMA Network Open. Here is a link to...
- Opportunities
- About
- The Latest
- Experts
Influence
January 9, 2020
Regenstrief VP breaking ground in artificial intelligence education in conjunction with National Academy of Medicine, other partners
Related News
Mobile Critical Care Recovery Program for Survivors of Acute Respiratory Failure: A Randomized Clinical Trial
Published in JAMA Network Open. Here is a link to the article. Regenstrief Institute authors: Babar Khan, M.D., M.S.,
Expanding health equity by including nursing home residents in clinical trials
INDIANAPOLIS – Clinical trials are constantly being designed and study participants enrolled to determine if medical treatments and therapies
Regenstrief Institute will host collaborative conference to improve public health data
Due to previous year’s high demand, virtual attendance option added The Public Health Informatics Program in the Center for
Study reports chlamydia and gonorrhea more likely to be treated per CDC guidelines in males, younger patients and individuals identifying as Black or multiracial
But significant numbers of those living with these diseases don’t receive this treatment INDIANAPOLIS – Chlamydia and gonorrhea are